FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387359557> ?p ?o ?g. }

• W4387359557 abstract "Abstract Disclosure: E. Ozsu: None. L. Akin: None. M. Aydin: None. M. Berberoglu: None. D. Stein: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. O. Pagovich: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. B. Olenchock: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. S. Podgrabinska: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. C.A. Harris: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. J. Mendell: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. R. SinhaRoy: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. J. Altarejos: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. B. Akinci: Advisory Board Member; Self; Amryt Pharmaceuticals, Regeneron, Third Rock Ventures. Consulting Fee; Self; Third Rock ventures, Regeneron, Amryt Pharmaceuticals. Speaker; Self; Astra Zeneca, Lilly, MSD, Novartis, Novo Nordisk, Sanofi Aventis. E.A. Oral: Advisory Board Member; Self; Third Rock Ventures, Regeneron, Rejuveneate Bio. Consulting Fee; Self; Amryt Pharmaceuticals, Regeneron. Grant Recipient; Self; Regeneron, Novo Nordisk, GI Dynamics, Ionis Pharmaceuticals, Fractyl, Rhythm Pharmaceuticals. Other; Self; Amryt Pharmaceuticals. Background: Congenital leptin deficiency (CLD) is a form of extreme obesity caused by biallelic pathogenic variants in the leptin gene. Recombinant human leptin normalizes weight and neuroendocrine/metabolic abnormalities in CLD, however, daily dosing is required with a risk of immunogenicity. Mibavademab is an investigational human leptin receptor agonist monoclonal antibody. Case report: A Turkish male infant came to medical attention due to rapid weight gain at 2 months of age and work-up led to identification of homozygous variant in the leptin gene causing CLD. He was treated with Metreleptin for 11 months starting at age 2. When weight regain despite Metreleptin therapy was noted, neutralizing antibody (Nab) was found to be strongly positive. He continued to gain weight rapidly causing impaired mobility, and required nightly oxygen with BIPAP. He was hospitalized frequently with upper respiratory tract infections and needed ICU care four times during the 5th year of his life. At age 5 years and 9 months and body weight of 89.9 kg (BMI SD:5.7), the compassionate use application to use Mibavademab was approved by the local ethics board and the Ministry of Health. The patient received an intravenous loading dose of Mibavademab followed by weekly subcutaneous (SC) administration of Mibavademab. SC dose and diet intake were carefully adjusted based on drug levels, and intended vs. observed weight loss. Results: Weight reduction was first observed in the first week of treatment, which was rapid with an average velocity of 7.1 kg/month until month 7. Upon dose adjustment, velocity decreased to 3.1 kg/month. Weight stabilization was achieved at month 11 at a weight of 28.9 kg (BMI SD:1.0) while using Mibavademab every two weeks. Overall, drug levels were significantly higher than projected in the first 28 weeks and then brought to predicted stable levels upon dose adjustments. Despite the rapid weight loss, improved mobility and age-appropriate growth were observed. There were no signs of precocious puberty. Glucose tolerance, insulinemia, and liver parameters all improved favorably over treatment period and there were no safety signals. The patient discontinued BIPAP treatment and sleep assumed a normal pattern without hypoxia. Conclusions: Compassionate treatment with Mibavademab for up to 60 weeks was associated with improvements in body weight and metabolic parameters, and was well-tolerated in a young child with CLD and Nab against metreleptin. Substantial benefits in mobility, social engagement, and respiratory status were also noted without adverse events. Mibavademab represents a potential new therapeutic option for patients with CLD and this first experience will provide guidance for treatment of similar patients. Presentation: Friday, June 16, 2023" @default.
• W4387359557 created "2023-10-06" @default.
• W4387359557 creator A5011581751 @default.
• W4387359557 creator A5019273939 @default.
• W4387359557 creator A5034975230 @default.
• W4387359557 creator A5039017951 @default.
• W4387359557 creator A5045147982 @default.
• W4387359557 creator A5046874152 @default.
• W4387359557 creator A5050031954 @default.
• W4387359557 creator A5056568967 @default.
• W4387359557 creator A5064989442 @default.
• W4387359557 creator A5071602087 @default.
• W4387359557 creator A5073272932 @default.
• W4387359557 creator A5080692046 @default.
• W4387359557 creator A5087737511 @default.
• W4387359557 creator A5091180238 @default.
• W4387359557 date "2023-10-01" @default.
• W4387359557 modified "2023-10-18" @default.
• W4387359557 title "FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency" @default.
• W4387359557 doi "https://doi.org/10.1210/jendso/bvad114.079" @default.
• W4387359557 hasPublicationYear "2023" @default.
• W4387359557 type Work @default.
• W4387359557 citedByCount "0" @default.
• W4387359557 crossrefType "journal-article" @default.
• W4387359557 hasAuthorship W4387359557A5011581751 @default.
• W4387359557 hasAuthorship W4387359557A5019273939 @default.
• W4387359557 hasAuthorship W4387359557A5034975230 @default.
• W4387359557 hasAuthorship W4387359557A5039017951 @default.
• W4387359557 hasAuthorship W4387359557A5045147982 @default.
• W4387359557 hasAuthorship W4387359557A5046874152 @default.
• W4387359557 hasAuthorship W4387359557A5050031954 @default.
• W4387359557 hasAuthorship W4387359557A5056568967 @default.
• W4387359557 hasAuthorship W4387359557A5064989442 @default.
• W4387359557 hasAuthorship W4387359557A5071602087 @default.
• W4387359557 hasAuthorship W4387359557A5073272932 @default.
• W4387359557 hasAuthorship W4387359557A5080692046 @default.
• W4387359557 hasAuthorship W4387359557A5087737511 @default.
• W4387359557 hasAuthorship W4387359557A5091180238 @default.
• W4387359557 hasBestOaLocation W43873595571 @default.
• W4387359557 hasConcept C185592680 @default.
• W4387359557 hasConcept C71924100 @default.
• W4387359557 hasConcept C98274493 @default.
• W4387359557 hasConceptScore W4387359557C185592680 @default.
• W4387359557 hasConceptScore W4387359557C71924100 @default.
• W4387359557 hasConceptScore W4387359557C98274493 @default.
• W4387359557 hasIssue "Supplement_1" @default.
• W4387359557 hasLocation W43873595571 @default.
• W4387359557 hasOpenAccess W4387359557 @default.
• W4387359557 hasPrimaryLocation W43873595571 @default.
• W4387359557 hasRelatedWork W1531601525 @default.
• W4387359557 hasRelatedWork W2319480705 @default.
• W4387359557 hasRelatedWork W2384464875 @default.
• W4387359557 hasRelatedWork W2398689458 @default.
• W4387359557 hasRelatedWork W2606230654 @default.
• W4387359557 hasRelatedWork W2607424097 @default.
• W4387359557 hasRelatedWork W2748952813 @default.
• W4387359557 hasRelatedWork W2899084033 @default.
• W4387359557 hasRelatedWork W2948807893 @default.
• W4387359557 hasRelatedWork W2778153218 @default.
• W4387359557 hasVolume "7" @default.
• W4387359557 isParatext "false" @default.
• W4387359557 isRetracted "false" @default.
• W4387359557 workType "article" @default.